 |
|
More patients needed in clinical trials to find treatment for heart condition linked to certain strokes
May 12, 2009The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth. Due to a lack of conclusive research on the management of PFO after stroke or transient ischemic attack, there is currently no clearly established treatment for this condition.
View the full science advisory here: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192272
This "call to action" advisory is published in Circulation: Journal of the American Heart Association and the Journal of the American College of Cardiology. The American Academy of Neurology has affirmed the value of this science advisory.
The advisory writing group notes there are a number of ongoing clinical trials looking at patients with PFO and cryptogenic strokes, which are strokes with no identifiable cause after an extensive search.
Enrollment in the trials has lagged and the off-label use of PFO closure devices has accelerated, jeopardizing the funding of some studies and the scientific validity of others. "Off-label" indicates when a device or drug is used to treat a condition not listed on its label. This is a common practice, especially for older drugs or devices that perhaps have found new uses but not been put through the rigors of FDA testing and approval for the new use.
"We must have enough patients followed for an adequate time in these trials to make the data valid and the findings strong," said Patrick O'Gara, M.D., chair of the writing group and director of Clinical Cardiology at Brigham and Women's Hospital in Boston. "The completion and peer review of these trials are critical to establishing the evidence base needed to help us make informed decisions regarding the best care for patients with this condition."
Potential treatments for PFO are important for reducing stroke risk. The advisory cites research that shows PFO present in 33.8 percent to 43.9 percent of patients with cryptogenic stroke. A PFO is usually detected by echocardiography during evaluations after a stroke.
Although "optimal" treatment for PFO isn't established, current options for treatment include drug therapy with either anti-platelet agents like aspirin or vitamin K antagonists such as warfarin, surgical repair, or closing the opening with catheter-based (percutaneous) devices. Surgical repair is not usually recommended unless a patient is already undergoing surgery for another reason.
Current American Heart Association/American Stroke Association guidelines recommend anti-platelet medication as the first-line therapy for PFO. Warfarin should be considered if there is an additional indication for anticoagulation. They say that there isn't enough evidence to recommend closing a PFO after a first stroke, but that closure may be considered for patients with recurrent cryptogenic stroke despite optimal medical therapy.
The choice between drug therapy and catheter-based repair has been intensely debated. To date, adequately powered, randomized, prospective clinical trials comparing drug therapy with catheter-based repair have yet to be completed.
Three Food and Drug Administration (FDA) advisory committee meetings (1997, 2002 & 2007) have affirmed the need for completing appropriately sized randomized controlled clinical trials to compare drug therapy with percutaneous device closure. As yet, no device for PFO closure is approved by the FDA.
In addition to the call for doctors to refer more patients to the ongoing trials, the advisory group recommends the data from these trials should be pooled where appropriate and that the "off-label" use of closure devices should be curtailed.
More information on the ongoing trials for patients with PFO can be found at http://www.clinicaltrials.gov and http://www.strokecenter.org/trials.
Co-authors include Gloria Catha, Steven R. Messe, M.D.; John C. Ring and E. Murat Tuzcu, M.D. Author disclosures are available on the manuscript.
American Heart Association
The advisory writing group notes there are a number of ongoing clinical trials looking at patients with PFO and cryptogenic strokes, which are strokes with no identifiable cause after an extensive search.
Enrollment in the trials has lagged and the off-label use of PFO closure devices has accelerated, jeopardizing the funding of some studies and the scientific validity of others. "Off-label" indicates when a device or drug is used to treat a condition not listed on its label. This is a common practice, especially for older drugs or devices that perhaps have found new uses but not been put through the rigors of FDA testing and approval for the new use.
"We must have enough patients followed for an adequate time in these trials to make the data valid and the findings strong," said Patrick O'Gara, M.D., chair of the writing group and director of Clinical Cardiology at Brigham and Women's Hospital in Boston. "The completion and peer review of these trials are critical to establishing the evidence base needed to help us make informed decisions regarding the best care for patients with this condition."
Potential treatments for PFO are important for reducing stroke risk. The advisory cites research that shows PFO present in 33.8 percent to 43.9 percent of patients with cryptogenic stroke. A PFO is usually detected by echocardiography during evaluations after a stroke.
Although "optimal" treatment for PFO isn't established, current options for treatment include drug therapy with either anti-platelet agents like aspirin or vitamin K antagonists such as warfarin, surgical repair, or closing the opening with catheter-based (percutaneous) devices. Surgical repair is not usually recommended unless a patient is already undergoing surgery for another reason.
Current American Heart Association/American Stroke Association guidelines recommend anti-platelet medication as the first-line therapy for PFO. Warfarin should be considered if there is an additional indication for anticoagulation. They say that there isn't enough evidence to recommend closing a PFO after a first stroke, but that closure may be considered for patients with recurrent cryptogenic stroke despite optimal medical therapy.
The choice between drug therapy and catheter-based repair has been intensely debated. To date, adequately powered, randomized, prospective clinical trials comparing drug therapy with catheter-based repair have yet to be completed.
Three Food and Drug Administration (FDA) advisory committee meetings (1997, 2002 & 2007) have affirmed the need for completing appropriately sized randomized controlled clinical trials to compare drug therapy with percutaneous device closure. As yet, no device for PFO closure is approved by the FDA.
In addition to the call for doctors to refer more patients to the ongoing trials, the advisory group recommends the data from these trials should be pooled where appropriate and that the "off-label" use of closure devices should be curtailed.
More information on the ongoing trials for patients with PFO can be found at http://www.clinicaltrials.gov and http://www.strokecenter.org/trials.
Co-authors include Gloria Catha, Steven R. Messe, M.D.; John C. Ring and E. Murat Tuzcu, M.D. Author disclosures are available on the manuscript.
American Heart Association
Stroke Current Events and Stroke News RSSStudy suggests dentists can identify patients at risk for fatal cardiovascular event
A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation.
Estrogen therapy likely must be given soon after menopause to provide stroke protection
For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience.
Researchers identify drug candidate for treating spinal muscular atrophy
A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants.
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
Clinical tests begin on medication to correct Fragile X defect
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability.
Brain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
A decade later, lifestyle changes or metformin still lower type 2 diabetes risk
Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data.
Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.
Research: Migraine and cardiovascular disease: Systematic review and meta-analysis
Migraine with aura (temporary visual or sensory disturbances before or during a migraine headache) is associated with a twofold increased risk of stroke, finds a study published on bmj.com today.
URI research couple's method targets cancerous tumors
Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.
More Stroke Current Events and Stroke News Articles
 |
Is This It by The Strokes With all the media hype that dogged the Strokes before the release of their debut album, it's rather apt that they chose the title Is This It. On the strength of just five songs released on two singles, the Strokes were being hailed as everything from the saviors of rock & roll to the Savior himself. Surely, few bands could live up to the impossibly high standards set for this young five-piece, but the band needn't have worried: Is This It is one of the most exciting and energetic debut albums to spring from New York's long-dormant club scene. In fact, the Strokes are a New York City band through and through; like the Velvet Underground, these are a bunch of uptown artsy types elegantly slumming downtown to the tried and tested themes of sex, drugs, and rock & roll. Their... |
 |
Room on Fire by The Strokes An acclaimed debut prompts one of two kinds of follow-ups: either the band strives to broaden their palate or they attempt to deepen the colors they splashed all over that heralded first effort. The Strokes' second outing falls in the latter camp. In the tradition of the Ramones' Leave Home and Oasis' (What's the Story) Morning Glory, the Strokes largely stay the course with their second full-length release, producing an album that won't cause the stir that its predecessor did, but has a sneaky appeal all its own. Thanks to the quintet's Lower East Side roots, Velvet Underground and Television references abound with these guys, but Boston new wavers the Cars, and in particular their hit-heavy second album, 1979's Candy-O, provide a more suitable point of reference for Room on Fire. As... |
 |
My Stroke of Insight: A Brain Scientist's Personal Journey by Ph.D., Jill Bolte Taylor (Author) The astonishing New York Times bestseller that chronicles how a brain scientist's own stroke led to enlightenment On December 10, 1996, Jill Bolte Taylor, a thirty-seven- year-old Harvard-trained brain scientist experienced a massive stroke in the left hemisphere of her brain. As she observed her mind deteriorate to the point that she could not walk, talk, read, write, or recall any of her life-all within four hours-Taylor alternated between the euphoria of the intuitive and kinesthetic right brain, in which she felt a sense of complete well-being and peace, and the logical, sequential left brain, which recognized she was having a stroke and enabled her to seek help before she was completely lost. It would take her eight years to fully recover. For Taylor, her stroke was a... |
 |
First Impressions of Earth by The Strokes Their prospects dangerously over-inflated by pundits who often hailed their debut as nothing short of rock-messianic, New York City's Strokes got a lesson in cynical rock-press dynamics when their biz-troubled, if similarly toned, '03 follow-up was dutifully dismissed as the proverbial sophomore slump. A lesser band might have been chastened by the experience; this one responds with a third album that positively bristles with energetic challenges. Revolving around a loose concept that allows songwriter/frontman Julian Casablancas to adopt a viewpoint that's as detached as it is world-weary and bemused, it's a record that quickly trades the often precious production conceits of its forebears for a muscular confidence that's notable from the infectious, back-to-the-'80s opener "You Only... |
 |
Is This It by The Strokes With all the media hype that dogged the Strokes before the release of their debut album, it's rather apt that they chose the title Is This It. On the strength of just five songs released on two singles, the Strokes were being hailed as everything from the saviors of rock & roll to the Savior himself. Surely, few bands could live up to the impossibly high standards set for this young five-piece, but the band needn't have worried: Is This It is one of the most exciting and energetic debut albums to spring from New York's long-dormant club scene. In fact, the Strokes are a New York City band through and through; like the Velvet Underground, these are a bunch of uptown artsy types elegantly slumming downtown to the tried and tested themes of sex, drugs, and rock & roll. Their... |
 |
Stronger After Stroke: Your Roadmap to Recovery by Peter G. Levine (Author) Billions of dollars are spent each year researching stroke rehabilitation and treatment techniques, but most are not well communicated to patients or caregivers. As a result, many stroke survivors are treated with outdated or ineffective therapies. Stronger After Stroke puts the power of recovery in the reader’s hands by providing easy instructions for reaching the highest possible level of healing. Written for stroke survivors, their caregivers, and their loved ones, the book presents a new approach that is startling in its simplicity: stroke survivors recover by using the same learning techniques that anyone uses to master anything. Basic concepts are covered, including repetition of task-specific movements, proper scheduling of practice, challenges at each stage of recovery, and... |
 |
The Stroke Billy Squier (Primary Contributor) |
 |
Is This It? by The Strokes 2002 reissue of their 2001 debut album includes the original track list with the controversial 'New York City Cops' which was replaced with 'Take It Or Leave It' on the US pressing. This import pressing also includes different artwork to the US version. The bonus DVD is in the NTSC/Region 0. The DVD (which features the same content as the US version) includes the bands 3 videos, 'Last Night', 'Hard To Explain' & 'Someday' as well as 2 un-aired live performances from MTV2's '2$Bill' show, 'Modern Age' & 'New York City Cops'. RCA. |
 |
First Impressions of Earth by The Strokes Their prospects dangerously over-inflated by pundits who often hailed their debut as nothing short of rock-messianic, New York City's Strokes got a lesson in cynical rock-press dynamics when their biz-troubled, if similarly toned, '03 follow-up was dutifully dismissed as the proverbial sophomore slump. A lesser band might have been chastened by the experience; this one responds with a third album that positively bristles with energetic challenges. Revolving around a loose concept that allows songwriter/frontman Julian Casablancas to adopt a viewpoint that's as detached as it is world-weary and bemused, it's a record that quickly trades the often precious production conceits of its forebears for a muscular confidence that's notable from the infectious, back-to-the-'80s opener "You Only... |
 |
Living With Stroke: A Guide for Families by Richard C Senelick (Author), Karla Dougherty (Author) Stroke doesn’t happen just to an individual, it happens to families, friends, and loved ones. Both HealthSouth and the American Stroke Association have long known this encompassing of stroke—it’s pain, it’s emotional damage, it’s debilitating after effects—not only on the survivors, but the loved ones in its wake. No one knows more that when stroke strikes, you need support, information, and advice fast. Finding this information has become a reassuring reality in this newest edition of Living With Stroke: A Guide for Families. Here, stroke patients and their families, friends, and caregivers can find the newest facts and figures on cutting edge of neural plasticity, constraint therapy, and more. Here, too, in clear, easy to understand language, is the entire process of... |
| © 2009 BrightSurf.com |